ArticleJournal of virology2025

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.

Tin Phan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.